Background. The emergence of kidney disease as an important comorbidity among human immunodeficiency virus (HIV)-infected patients receiving highly active antiretroviral therapy (HAART) has emphasized the critical importance of early identification of patients at risk for kidney disease. Use of urine as a diagnostic medium may allow the noninvasive detection of incipient nephropathy in these patients. Methods. Here, we conducted cross-sectional and 1-year prospective studies of 424 HIV-infected patients on HAART without proteinuria or significant impairment of glomerular function. N-acetyl-b-D-glucosaminidase, c-glutamyl transpeptidase, b 2 -microglobulin and a 1 -microglobulin were measured as indices of tubular damage, which was diagnosed when urinary concentrations of at least three tubular biomarkers exceeded the reference range. Risk factors associated with tubular damage were examined using multivariate logistic regression analysis. Results. Tubular damage was identified in 107 patients (25%), who were characterized by advanced age [odds ratio (OR), 1.04; 95% confidence interval (CI), 1.01-1.07], high C-reactive protein (OR, 1.96; 95% CI, 1.26-3.14) and coexisting diabetes mellitus (OR, 3.97; 95% CI, 1.44-12.2). The use of tenofovir, the most likely tubulotoxic agent, was not statistically involved in this subclinical tubular damage. The 1-year follow-up study showed that a decrease in estimated glomerular filtration rate (eGFR) and incidence of proteinuria during the period were significantly higher in patients with than without tubular damage. Conclusions. A quarter of HIV-infected patients receiving HAART had subclinical tubular damage, which was associated with a near-term decline in eGFR and higher incidence of proteinuria. Periodic monitoring of urinary biomarkers might facilitate the early identification of HAART patients predisposed to significant kidney disease.
Introduction
Although highly active antiretroviral therapy (HAART) has prolonged the survival of human immunodeficiency virus (HIV)-infected patients, this improvement has been accompanied by an increase in the incidence of comorbidities, including kidney disease [1] [2] [3] [4] [5] . HAART appears to inhibit the development of HIV-associated nephropathy (HIVAN) to progressive renal failure and subsequent end-stage renal disease (ESRD) [6] [7] [8] . Despite this, the prevalence of ESRD in HIV-infected patients has increased even though the incidence of ESRD attributed to HIVAN has remained constant since the introduction of HAART [9] [10] [11] . While the increased prevalence of ESRD due to HIVAN is likely to be a result of increased survival of these patients, longterm HAART may contribute to the development of chronic kidney disease in some patients [12, 13] .
Several HAART agents have been shown to have side effects with regard to nephrotoxicity and metabolic disorders, such as diabetes and hyperlipidemia, both of which might be synergistically involved in kidney disease [12] [13] [14] [15] . Among them, tenofovir disoproxil fumarate (TDF) is actively and primarily secreted at the level of the proximal tubule and might induce tubular damage as a result of severe mitochondrial dysfunction [12, 16, 17] . In general, kidney disease due to nephrotoxic drugs can be identified in its early stage through the measurement of urinary biomarkers [18] [19] [20] . However, the usefulness of urinary biomarkers in screening for early kidney disease in HIV-infected patients on HAART is unknown. In this context, several recent studies have used evaluation of urinary parameters, including urinary biomarkers, to show that a substantial minority of HIV-infected patients on HAART has renal tubular toxicity in the absence of impaired glomerular function [21] [22] [23] . The near-or long-term consequences of this tubulopathy have yet to be clarified.
Here, we investigated the development of kidney tubular damage in the absence of glomerular defects in HIV patients treated with HAART and risk factors associated with this damage, using conventional urinary biomarkers of proximal tubular damage including N-acetyl-b-Dglucosaminidase (NAG), c-glutamyl transpeptidase (cGT), b 2 -microglobulin (b 2 M) and a 1 -microglobulin (a 1 M) [20] . We also conducted a follow-up study to examine near-term outcomes for patients with this tubular damage, which have not been previously evaluated.
Materials and methods

Subjects
This study combined cross-sectional and 1-year follow-up designs to determine the presence of kidney tubular damage in the absence of overt evidence of glomerular abnormalities and to examine the short-term consequences of tubular damage. The subjects consisted of 424 HIVinfected outpatients who visited Tokyo Metropolitan Komagome Hospital at least once a month for clinical care. All patients had provided a random urine and blood sample between 1 February 2008 and 30 April 2009; had received HAART and had no significant glomerular defects as determined by proteinuria and glomerular dysfunction. They were classified into two subgroups by current HAART regimen, namely (i) one to three nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) with one or two protease inhibitors (PIs) (PI-containing regimen group: n ¼ 283) and (ii) one to three NRTIs with a non-NRTI (NNRTI) (non-PI-containing regimen group: n ¼ 141). NRTIs included TDF (n ¼ 243), abacavir (n ¼ 71), zidovudine (n ¼ 85), stavudine (n ¼ 36), didanosine (n ¼ 17), lamivudine (n ¼ 337) and emtricitabine (n ¼ 112). PIs included ritonavir (n ¼ 251), atazanavir (n ¼ 177), fosamprenavir (n ¼ 13), lopinavir (n ¼ 63) and nelfinavir (n ¼ 24). NNRTI included efavirenz only (n ¼ 141). Mean patient age and HAART duration were 45.6 AE 11.0 and 6.56 AE 3.54 years, respectively. HAART type and doses of antiretroviral drugs were not changed in any patient during the follow-up period. Patients had no prior history of apparent HIVAN and no current or recent use of nonsteroidal anti-inflammatory drugs; nephrotoxic agents, such as acyclovir, ganciclovir, adefovir, pentamidine, trimethoprim/sulfamethoxazole or amphotericin B or aminoglycosides; or contrast enhancement agents. Alcohol consumption and illicit drug use were not assessed.
Methods
Height, weight and blood pressure were measured using standardized protocols. Hypertension was defined as a systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg or the use of antihypertensive agents at baseline. Diabetes mellitus (DM) was defined as a diagnosis of DM prior to baseline or use of oral antidiabetic agents or insulin at baseline. CD4 lymphocyte counts were determined using a specific monoclonal antibody and fluorescence-activated cell-sorter analysis. HIV RNA viral load was measured using the Roche Amplicor Monitor reverse transcription-polymerase chain reaction assay (Roche Molecular Systems, Tokyo, Japan; lower detection limit, 50 copies/mL). If the viral load was undetectable, a value of 50 copies/mL was assigned for statistical analysis. Serum and urinary creatinine (Cr) was measured by an enzymatic method using an isotope-dilution mass spectrometry-traceable calibrator (N-assay L Creatinine Kit; Nittobo Medical Co. Ltd., Tokyo, Japan). The following parameters were measured in all patients using conventional methods: serum total protein (TP), serum alumin (Alb), serum total cholesterol (TC), serum triglycerides (TG), C-reactive protein (CRP) and hemoglobin (Hb). Urinary concentrations of NAG, b 2 M, a 1 M and cGT were measured as follows: NAG and cGT were measured by colorimetric assay of enzyme activity with 6-methyl-2-pyridyl-N-acetyl-1-thio-6-D-glucosaminide and L-c-glutamyl-3-carboxy-4-nitroanilide plus glycylglycine (Nittobo Medical Co. Ltd.) as substrates, respectively; b 2 M by immuno-enzymometric assay (E test TOSOH II BMG; TOSOH Corporation, Tokyo, Japan) and a 1 M with a latex aggregation assay kit (Eiken a 1 M-III; Eiken Chemical Co., Ltd., Tokyo, Japan). Concentrations of urinary biomarkers were standardized to a urinary Cr of 1 g/L (/g Cr). Tubular damage was diagnosed when urinary concentrations of three or more tubular biomarkers exceeded the reference ranges given by the manufacturers. Proteinuria was defined as !11 on urine dipstick examination. Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease study equation, adjusted for Japanese [24] . Proteinuria and eGFR were examined by at least two consecutive analyses conducted 3 months apart. Overt glomerular defect was defined as a sustained eGFR below 60 mL/min/1.73m 2 or persistent proteinuria for a period of >3 months. The present study was conducted in accordance with the Declaration of Helsinki and approved by the institutional review board of Tokyo Metropolitan Komagome Hospital (the certificate no. of the approval: 681-09-1-13). Informed consent was obtained from all patients prior to enrollment.
Statistics
Descriptive statistics were used to demonstrate the difference between HIV patients with and without kidney tubular damage. All data are expressed as the mean AE SD unless otherwise stated. Common log transformation was applied when necessary. Characteristics of patients with and without kidney tubular damage were compared for statistical significance using the Mann-Whitney U-test for continuous variables and the chi-square test for categorical variables. Analysis of paired observations in the 1-year follow-up study was performed using the paired t-test. Multivariate logistic regression analysis was used to evaluate the relationship between the presence of kidney tubular damage and clinical characteristics, adjusted for potential confounders of kidney disease. We built multivariate models using both the forward and backward stepwise methods. Entry and elimination criteria were set at a value of P ¼ 0.10, which is one of the default value sets for the stepwise procedure of the JMP statistical package. All statistical analyses were performed using the JMP 8 statistical software application (SAS Institute Japan, Tokyo, Japan). All P-values are two-sided and a value of P <0.05 was considered statistically significant.
Results
Prevalence of tubular damage in the absence of glomerular defects A cross-sectional study was conducted in 424 HIV-infected patients on HAART who demonstrated neither proteinuria nor a decrease in eGFR below 60 mL/min/1.73m 2 at baseline. Coexisting tubular damage in the absence of overt glomerular defects was found in 107 patients (25%).
Demographic and laboratory characteristics in HIV-infected patients with and without tubular damage
Characteristics of patients with and without tubular damage are given in Table 1 . Age, proportion of DM, proportion of current smokers, HIV RNA level, serum TC level, serum CRP level and HAART duration were significantly higher in those with than without tubular damage. Additionally, urinary levels of NAG, b 2 M, a 1 M and cGT were significantly higher in the tubular damage group. Hb concentration was significantly lower in those with than without tubular damage. In contrast, the two groups did not differ with respect to use of typical HAART agents and combinations; gender; body mass index; CD4 lymphocyte count; nutritional markers such as serum TP, serum Alb and serum TG and the presence or absence of hypertension or hepatitis B virus (HBV) or hepatitis C virus infection. Furthermore, no differences were seen in serum Cr level or eGFR.
Factors associated with renal tubular damage in the study population
Multivariate logistic regression analysis showed factors associated with renal tubular damage ( 2 ). The difference between eGFR at baseline and at the follow-up was not significant in both the diabetic and nondiabetic groups (P ¼ 0.3314). The incidence of proteinuria during this period was 18.7% (20 of 107 patients) in patients with and 6.9% (22 of 317 patients) in those without tubular damage, with this difference between the increase in rates being statistically significant (P ¼ 0.0084). The incidence of proteinuria was 28.6% (6 of 21 patients) in diabetic patients, which was significantly higher than that in nondiabetic patients (8.9%; 36 of 403 patients; P ¼ 0.0115).
Discussion
Approximately 25% of HIV patients on HAART had tubular damage but no overt glomerular defects. Tubular damage was significantly associated with advanced age, higher CRP levels and coexistence of DM. Glomerular function decreased in these patients with tubular damage during the follow-up period, and the incidence of proteinuria increased. These findings suggest that the detection of subclinical tubular damage using urinary biomarkers may allow significant kidney disease to be identified before any overt evidence of glomerular defects can be obtained.
Our finding that patients with tubular damage developed overt kidney disease during the 1-year follow-up period may raise issues concerning the development of kidney disease in HIV-infected patients on HAART. A previous study found that of 183 HIV patients on HAART without loss of kidney function, 18% had tubular damage [21] , while another reported a prevalence of tubular damage (urinary b 2 -microglobulin level > 500 lg/L) of 42.9% in TDF (1) HAART patients versus 7.8% in those who were TDF (À) [23] . Neither study clarified the coexistence of proteinuria in the cohorts, however, which hampers comparison with our present study. In addition, as these previous studies did not examine future outcomes of the tubulopathy, it is unclear whether their cohorts were at risk for progressive kidney disease. Kidney tubular damage is usually an initial sign of kidney disease, particularly that related to toxic drugs and ischemia, and the resulting kidney disease is thus usually restricted to tubular cells or a specific region of the nephron [20, 25] . Our results suggest that with progression, this damage becomes more complex, as reflected by the development of proteinuria and a decrease in glomerular function in HIV-infected patients on HAART. Periodic screening of subclinical tubulopathy using these urinary biomarkers therefore appears to be a simple and noninvasive means of identifying HIV-infected patients on HAART at risk of kidney disease, including an impending decline in kidney function.
Our study showed that coexisting diabetes and higher age were associated with tubular damage in the HIV population on HAART. In addition to change in intrarenal blood flow, numerous other anatomical and functional changes occurring in the diabetic and aging kidney are likely responsible for tubular damage. The hypoxic milieu in the early-stage diabetic kidney is induced by any of the several factors, including manifestations of chronic hyperglycemia-related abnormalities of red blood cells, atherosclerosis, oxidative stress, sympathetic denervation of the kidney due to autonomic neuropathy and DM-induced tubular apoptosis; on this basis, tubulointerstitial hypoxia in DM might be an important early event in the course of overt kidney disease [26] [27] [28] . Thomas et al. [29] showed that tubulointerstitial fibrosis is an active process associated with interstitial inflammation and fibroblast activation in aging kidney and that the tubulointerstitial injury in aging may be a consequence of ischemia secondary to peritubular capillary damage. These findings raise the possibility that diabetic and aged HIV patients have tubular damage prior to the emergence of overt glomerular disease. A mildly elevated CRP level is a marker of systemic low-grade inflammation, which is considered to reflect systemic microvascular atherosclerotic injury [30] . The kidney in HIV-infected patients is characterized by many structural changes [31] , which include those due to various chronic disorders, such as hypertension, DM and atherosclerosis, which are highly prevalent in current HIV-infected patients on HAART [4, 5] . As mentioned above, peritubular capillary damage due to either or both DM-and age-related atherosclerotic changes potentially induces interstitial ischemia and inflammation, which may be revealed by the elevation of CRP level.
There is a growing body of evidence from retrospective case reports of changes in kidney function associated with the use of TDF. In contrast, TDF-associated kidney dysfunction is a rare event in prospective clinical trials, particularly when administered to patients with no overt glomerular defects [4, 5, [32] [33] [34] . In our study also, we saw no association between the frequency of use of HAART agents, either individually or in combination, with the likelihood of developing tubular damage, albeit that the lack of detailed data on cumulative dose and time of administration for individual HAART agents inherent to our cross-sectional study design hinders any clear understanding of such association. This may simply suggest that there is a background level of proximal tubular damage in patients receiving HAART that is not necessarily specific to TDF.
This study has several limitations. First, the analysis was based on the measurements of renal parameters only, as the patients did not show clinical kidney disorders, renal biopsy to confirm the presence of tubular damage was not performed. Second, because total drug exposure time and doses throughout the clinical course were not recorded for all HIV individuals, we did not assess the time or dose dependency of the effect of nephrotoxic agents, including TDF, on tubular damage. Third, the study sample was mostly limited to Japanese subjects and did not include blacks who were considered to be at high risk for kidney disease. This might affect the generalizability of the current results. Finally, quantitation of proteinuria was not performed in this study. Proteinuria defined as !11 on spot urine dipstick examination may or may not reflect abnormal proteinuria as it depends on the urinary concentration.
In conclusion, this study suggests that~25% of HIVinfected patients receiving HAART may have kidney tubular damage in the absence of glomerular defects, likely leading to a near-term decline in glomerular function and higher incidence of proteinuria. Periodic monitoring of urinary biomarkers might be useful in the early identification of patients at risk for overt kidney disease. From the perspective of renal safety, this study underscores the importance of monitoring patients on HAART for tubular injury before the emergence of substantial glomerular dysfunction.
